BIA 3-202, a novel catechol-O-methyltransferase inhibitor, enhances the availability of l-DOPA to the brain and reduces its O-methylation

By Parada A.   Loureiro A.I.   Vieira-Coelho M.A.   Hainzl D.   Soares-da-Silva P.  

European Journal of Pharmacology, Vol. 420, Iss. 1, 2001-05 ,pp. : 27-32

Elsevier

Access to resources Recommend Favorite

Entacapone, a novel catechol-O-methyltransferase inhibitor for Parkinson's disease, does not impair mitochondrial energy production

By Nissinen E.   Kaheinen P.   Penttila K.E.   Kaivola J.   Linden I.-B.  

European Journal of Pharmacology, Vol. 340, Iss. 2, 1997-12 ,pp. : 287-294

Elsevier

Access to resources Recommend Favorite

Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-DOPA and dopamine in rats

By Napolitano A.   Zurcher G.   Da Prada M.  

European Journal of Pharmacology, Vol. 273, Iss. 3, 1995-02 ,pp. : 215-221

Elsevier

Access to resources Recommend Favorite

Inhibitors of Catechol-O-Methyltransferase

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 11, Iss. 3, 2012-05 ,pp. : 324-332

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacokinetics and Pharmacodynamics of BIA 3-202, a Novel COMT Inhibitor, during First Administration to Humans

By Almeida L.   Soares-da-Silva P.  

Drugs in R&D, Vol. 4, Iss. 4, 2003-01 ,pp. : 207-217

Adis International

Access to resources Recommend Favorite